LifeMD (LFMD)
(Delayed Data from NSDQ)
$5.28 USD
+0.04 (0.76%)
Updated Sep 19, 2024 04:00 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
LFMD 5.28 +0.04(0.76%)
Will LFMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LFMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LFMD
LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
LFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
Other News for LFMD
LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment Options
LifeMD announces major enhancements to its weight management program
LifeMD's Series A Preferred Stock Yield Pushes Past 10%
LifeMD: Selling WorkSimpli Could Be A Catalyst
Craig-Hallum Keeps Their Buy Rating on LifeMD (LFMD)